Summary & Overview
HCPCS J0283: Amiodarone Hydrochloride Injection, 30 mg
HCPCS Level II code J0283 denotes a 30 mg injection of amiodarone hydrochloride (nexterone), an intravenous antiarrhythmic used in acute care settings. Nationally, accurate coding for IV amiodarone is critical for proper clinical documentation, claims adjudication, and cost reporting given its use in emergency and inpatient cardiac care.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes payer coverage patterns, coding and billing considerations, and clinical context for use of amiodarone injections across typical sites of service.
Readers will learn: benchmarking information for utilization and reimbursement where available; clinical context supporting use of IV amiodarone in arrhythmia management; common billing modifiers and administrative considerations (listed separately); and guidance on documentation elements tied to this HCPCS Level II code. Data limitations are noted where input elements were not provided. The material is intended for billing managers, revenue cycle professionals, and clinical staff involved in hospital and emergency medication administration to support accurate claims submission and recordkeeping.
Billing Code Overview
HCPCS Level II code J0283 represents an injection of amiodarone hydrochloride (nexterone), 30 mg. This code is used to report administration of the specified intravenous antiarrhythmic agent.
Service type: Intravenous medication administration
Typical site of service: Hospital inpatient or outpatient setting, emergency department, or other acute care facility where IV antiarrhythmic therapy is administered
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with a history of ischemic cardiomyopathy and recurrent ventricular tachycardia is admitted to the cardiac care unit with sustained ventricular arrhythmia refractory to initial electrical cardioversion and rate-control measures. The cardiology team elects to administer intravenous amiodarone for arrhythmia suppression. Medication is prepared as J0283 (Injection, amiodarone hydrochloride (nexterone), 30 mg) and delivered via intravenous bolus followed by continuous infusion per facility protocol. Typical workflow: emergency department or inpatient cardiology consult → order placed in electronic health record with dose and infusion instructions → pharmacy compounds and labels the J0283 syringes or IV bags per sterile compounding standards → bedside nurse verifies patient identity, allergy status, and concurrent medications → administer J0283 with continuous cardiac monitoring in an appropriate monitored bed (ED, telemetry floor, or intensive care unit) → document administration, response, and any adverse effects (hypotension, bradycardia, QT prolongation) in the medical record. Typical site of service: hospital inpatient, emergency department, or observation unit; also used in procedural suites when intra-procedural arrhythmia control is needed. Typical patient scenario: acute treatment of life‑threatening supraventricular or ventricular arrhythmias or peri-procedural arrhythmia management in hospitalized adults with continuous monitoring and pharmacy oversight.
Coding Specifications
| Modifier | Description | When to Use |
|---|